- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01174173
Ranolazine and Pulmonary Hypertension
Effects of Ranolazine in Patients With Angina Due to Right Ventricular Ischemia in Pulmonary Arterial Hypertension
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is looking to enroll patients with pulmonary hypertension (PH). PH is abnormally high blood pressure in the arteries of the lungs. It makes the right side of the heart need to work harder than normal and is usually caused by a narrowing of the small arteries of the lung. This narrowing makes it harder for the right side of the heart to circulate the blood to the lungs. Over time, the right side of the heart may become enlarged and symptoms (such as angina [chest pain] shortness of breath, fatigue, edema) begin to appear.
Ranolazine is a safe, well-tolerated, and FDA-approved medication for the treatment of chronic stable angina. Ranolazine may potentially improve blood flow to the right ventricle (RV), thereby relieving angina while simultaneously improving RV performance and contractility. This latter effect may increase stroke volume and cardiac output which could translate into benefits in exercise capacity and improved quality of life.
The purpose of this single center, non-randomized, prospective pilot study is to investigate the effects of 3 months treatment with ranolazine on pulmonary artery hemodynamics, exercise capacity and quality of life in patients with PAH and symptoms of angina or angina equivalent.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- World Health Organization (WHO) Group 1 PAH, defined as a pulmonary hypertension with mean pulmonary artery pressure > 25 mmHg, pulmonary capillary wedge pressure < 15 mmHg, and pulmonary vascular resistance > 3 Wood units.
- Right ventricular dysfunction, defined as RV fractional area change < 32% or RV tricuspid annular plane systolic excursion (TAPSE) < 15 mm.
- Symptoms of angina or angina equivalent (exertional dyspnea, exertional epigastric pain, exertional nausea).
- New York Heart Association functional class II or III symptoms.
- Stable doses of pulmonary vasodilators (prostacyclins, endothelin receptor antagonists, phosphodiesterase inhibitors), with no new therapy initiation or dose escalation > 50% in the 4 weeks prior to randomization.
- Age 18-80 years.
Exclusion criteria:
- Acute coronary syndrome or coronary revascularization within the prior 3 months.
- Patients with unstable angina.
- Patients with Class IV congestive heart failure.
- Planned revascularization, pacemaker or defibrillator placement during the study period.
- Changes in antianginal medical therapy likely to occur during the study period.
- Corrected QT interval measurement >500 ms.
- Patients with pre-existing QT prolongation (including congenital long QT syndrome) or receiving other QT prolonging drugs (including Class Ia-e.g., quinidine, Class III-e.g., dofetilide, sotalol, antiarrhythmics; antipsychotics (e.g., thioridazine, ziprasidone), or known history of complex ventricular arrhythmias requiring antiarrhythmic medications or ICD implantation.
- Patients with known history of hepatic dysfunction.
- Current use of strong CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, saquinavir and diltizaem.
- Patients with pacemakers, cochlear implants, aneurysm clips, who have worked with metal.
- Patients with metallic hardware, implants, or prostheses will consult with the radiologist/cardiologist prior to the study.
- Patients with severe or end stage renal disease (an estimated GFR < 30 mL/min/1.73 m).
- Women who are pregnant or lactating
Any contraindications for the use of a right heart catheter including, but not limited to:
- Pulmonic or tricuspid valve stenosis
- Prosthetic pulmonic or tricuspid valve
- Right atrial or ventricular masses
- Previous pneumonectomy
- Risk of severe arrhythmias, including left bundle branch block (LBBB)
- Subjects unable to perform cardiopulmonary exercise testing will be excluded (i.e. extensive musculoskeletal disease)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ranolazine
1000 mg PO BID
|
ranolazine 1000 mg PO BID for 3 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improve Angina Symptoms
Time Frame: 3 months
|
Assessed as average improvement in WHO Functional Class.
The WHO Functional Class score ranges from 1 to 4, with higher scores indicating more impairment
|
3 months
|
6-Minute Walk Test
Time Frame: 3 Months
|
Improve Exercise Capacity measured by 6-Minute Walk Test
|
3 Months
|
Improve Quality of Life
Time Frame: 3 Months
|
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.
The scores are averaged and transformed to a range of 0-100, in which higher scores reflect better health status and was performed at the conclusion of the study.
|
3 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RV Perfusion on Cardiac MRI
Time Frame: 3 months
|
The majority of patients did not undergo cardiac MRI because it was difficult for the patients to tolerate the imaging study.
Therefore, we were not able to assess change in RV perfusion.
|
3 months
|
Absolute RV Longitudinal Strain
Time Frame: 3 months
|
Change in absolute right ventricular (RV) longitudinal strain as assessed by exercise stress echocardiography with speckle-tracking echocardiography at baseline and conclusion of the study.
An increase in exercise-induced change in RV longitudinal strain between baseline to conclusion of the study is indicative of improved RV function.
If absolute RV longitudinal strain increases with exercise, that is a sign that the RV is working well.
If absolute RV longitudinal strain decreases with exercise, that is a sign that the RV is not working well.
Therefore, between baseline and conclusion of the study, if exercise-induced change in RV strain increases that means that the RV is working better at the conclusion of the study.
|
3 months
|
Right Ventricular Hemodynamics
Time Frame: 3 months
|
Mean pulmonary artery pressure was assessed invasively by right heart catheterization at the conclusion of the study to estimate right ventricular hemodynamics.
|
3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sanjiv Shah, MD, Northwestern University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Pain
- Neurologic Manifestations
- Hypertension, Pulmonary
- Chest Pain
- Hypertension
- Pulmonary Arterial Hypertension
- Familial Primary Pulmonary Hypertension
- Angina Pectoris
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Sodium Channel Blockers
- Ranolazine
Other Study ID Numbers
- STU00030314
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Regina Steringer-MascherbauerUnknownPulmonary Arterial Hypertension WHO Group IAustria
Clinical Trials on Ranolazine
-
University of Kansas Medical CenterGilead SciencesUnknown
-
University of California, San DiegoTerminatedDiastolic Heart Failure | Echocardiography | Ranolazine | Tissue Doppler UltrasoundUnited States
-
University CardiologyUnknownIschemic Mitral RegurgitationUnited States
-
Kent Hospital, Rhode IslandGilead SciencesCompletedMyocardial Ischemia | Ventricular Premature ComplexesUnited States
-
Cardiovascular Consultants of NevadaGilead SciencesUnknownCoronary Artery Disease | Atrial Fibrillation | Ventricular Tachycardia | Chronic Stable AnginaUnited States
-
Gilead SciencesCompletedMyocardial Ischemia | Myocardial Perfusion ImagingUnited States, Finland, Israel, Canada, Italy, Singapore, Czech Republic, United Kingdom
-
Novartis PharmaceuticalsTerminatedAtherosclerotic Coronary Vascular DiseaseUnited States
-
Gilead SciencesCompletedCoronary Artery Disease | Type 2 Diabetes Mellitus | Angina PectorisCanada, Slovenia, United States, Israel, Germany, Georgia, Russian Federation, Czech Republic, Belarus, Bulgaria, Poland, Serbia, Slovakia, Ukraine
-
Gilead SciencesCompletedAtrial FibrillationUnited States, Italy, Poland, Germany, Israel, Netherlands, United Kingdom
-
IRCCS San RaffaeleMenarini International Operations Luxembourg SACompletedHCM - Hypertrophic Non-Obstructive CardiomyopathyItaly